European Psychiatry - Volume 33 - March 2016

402 / 812

S398 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
Further reading
FOBIAS ESPECÍFICAS, Bados, Arturo.
.
EV150
Nonlinear electroencephalogram
analyse cortical functional activity in
patients with generalized anxiety
disorder
Y. Wang
Guiyang Medical University, Department of Psychiatry, Guiyang,
China
Background The neurological correlates of generalised anxiety
disorder (GAD) are not well known, however there is evidence of
cortical dysregulation in patients with GAD. The aim of the study
was to examine cortical functional activity in patients with GAD
using nonlinear electroencephalogram (EEG) analysis, and to eval-
uate the contribution of anxiety severity.
New method The sample consisted of 64 outpatients diagnosed
with GAD, anxiety severity was assessed using the Hamilton Rat-
ing Scale for Anxiety (HAMA) severity score, with 7–17 scores
indicating mild anxiety as A group and 18 and above indicating
moderate-severe anxiety as B group. EEGs were conducted, and
between-group differences on non-linear parameter Correlation
Dimension (D2) were analyzed. The association between D2 value
and HAMA scores was analysed.
Results Compared with the control group, D2 values were
increased in anxiety groups. For those with mild anxiety, this
difference occurred only in the left prefrontal regions. For those
withmoderate-severe anxiety, significantly greater D2 values were
observed in all of the cerebral regions, especially in the left and right
temporal and other left cerebral regions. When compared with
those with mild anxiety, D2 values were significantly greater for
those with moderate-severe anxiety in the left and right temporal
lobe and all other left cerebral regions.
Conclusions GADwas significantly associated with dysfunctional
cortical activity in the majority of cerebral regions, GAD severity
was associated with involvement of a larger number of cerebral
regions. This analysis method is suggested as a complementary tool
to examine dysfunctional cortical activity in GAD.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
Bipolar disorders
EV151
Do bipolar II and bipolar I disorder
have different genotypes and why do
we observe unipolar depression
converting to bipolar II and then
bipolar I?
M. Agius ∗, M. Fawcett , R. Zaman
1 University of Cambridge, Psychiatry, Cambridge, United Kingdom
2 University of Cambridge, School of Clinical Medicine, Cambridge,
United Kingdom
∗ Corresponding author.
We review the recent literature in order to establish the impor-
tance of a spectrum for bipolar affective disorder, and that unipolar
depression, bipolar II and bipolar I are discrete entities that may
however evolve in sequence. We discuss clinical, genetic and neu-
robiological data which illustrate the differences between bipolar I
and bipolar II. To fit the data we suggest a series of multiple mood
disorder genotypes, some of which evolve into other conditions on
the bipolar spectrum. Thence, we discuss the nature of the bipolar
spectrum and demonstrate how this concept can be used as the
basis of a staging model for bipolar disorder.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV152
Use of lithium in acute mania in
adolescents
C. Aksoy Poyraz ∗, A. Özdemir , G. Günay , B.C¸ . poyraz ,
S. Enginkaya , G. Karac¸ etin , N. Tomruk
1 Istanbul University Cerrahpas¸ a Faculty of Medicine, psychiatry,
Istanbul, Turkey
2 Bakırköy Mazhar Osman Mental Health and Neurological Diseases
Education and Research Hospital, psychiatry, Istanbul, Turkey
∗ Corresponding author.
The aim of the present study was to investigate whether the use of
lithium followed recommended practice in acutely manic adoles-
cent inpatients. This study was a 12-month retrospective review of
patients with manic episode admitted to Bakırköy Mazhar Osman
Mental Health and Neurological Diseases Education and Research
Hospital. Length of stay, medication data, serum levels and adverse
effects were recorded for patients who started lithium treatment
within average of 7 days of admission ( n = 52). Average length of
stay was 23.63 (SD = 17.6). The maximum dose prescribed within
24 h of starting treatment was 721.15mg (SD = 239.5). The maxi-
mum daily dose was reached in an average of 7 days to 1136.5mg
(SD = 336.4). The average time after starting treatment until the first
recorded serum level was 5 days. The average serum level reached
was 0.5mEq/L (SD = 0.22), which was raised to 0.6mEq/L (SD = 0.3)
at discharge with an average daily dose of 1038.46mg (SD = 460).
In 8 admissions (15.4%), one adverse effect was recorded that could
have been related to lithium treatment but adverse events did not
lead to discontinuation of drug. The literature supports that rapidly
attained high serum levels are associated with positive outcomes.
In this current study, clinicians used a relatively slow dose titra-
tion and lower serum levels were obtained suggesting that lithium
was not considered as a primary agent for treating mania. Taking
advantage of lithium especially for the maintenance treatment of
bipolar disorder and tolerability may have driven these findings.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV153
Mental health and drug
R. Alonso Díaz ∗ ortázar Alonso
H. Guillén Rodrigo
1 Hospital Juan Ramón Jiménez, Huelva, Spain
2 Hospital Juan Ramón Jiménez, Salud Mental, Huelva, Spain
∗ Corresponding author.
Introduction Bipolar disorder (BD) is often associated with var-
ious comorbidities. It is substance use disorders (SUD) one of the
most frequent comorbidities.
The ECA study (Epidemiologic Catchment Area) observed a preva-
lence over the life of the 56, 1% for any TUS in the total sample of
patients with bipolar disorder. In subjects with bipolar I disorder
prevalence was 60.7%, and those of type II 48.1.